Preclinical Development of New Therapy for Glycogen Storage Diseases
- 22 July 2015
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 15 (4) , 338-347
Abstract
Glycogen storage disease (GSD) consists of more than 10 discrete conditions for which the biochemical and genetic bases have been determined, and new therapies have been under development for several of these conditions. Gene therapy research has generated proof-of-concept for GSD types I (von Gierke disease) and II (Pompe disease). Key features of these gene therapy strategies include the choice of vector and regulatory cassette, and recently adeno-associated virus (AAV) vectors containing tissue-specific promoters have achieved a high degree of efficacy. Efficacy of gene therapy for Pompe disease depend upon the induction of immune tolerance to the therapeutic enzyme. Efficacy of von Gierke disease is transient, waning gradually over the months following vector administration. Small molecule therapies have been evaluated with the goal of improving standard of care therapy or ameliorating the cellular abnormalities associated with specific GSDs. The receptor-mediated uptake of the therapeutic enzyme in Pompe disease was enhanced by administration of β2 agonists. Rapamycin reduced the liver fibrosis observed in GSD III. Further development of gene therapy could provide curative therapy for patients with GSD, if efficacy from preclinical research is observed in future clinical trials and these treatments become clinically available.Keywords
This publication has 98 references indexed in Scilit:
- β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe diseaseMolecular Genetics and Metabolism, 2012
- Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscleMolecular Genetics and Metabolism, 2011
- Antibody formation and mannose‐6‐phosphate receptor expression impact the efficacy of muscle‐specific transgene expression in murine Pompe diseaseThe Journal of Gene Medicine, 2010
- Neonatal Gene Therapy of Glycogen Storage Disease Type Ia Using a Feline Immunodeficiency Virus–based VectorMolecular Therapy, 2010
- Oxidative stress mediates nephropathy in type Ia glycogen storage diseaseLaboratory Investigation, 2010
- Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib miceJournal of Hepatology, 2009
- AAV2/8-mediated Correction of OTC Deficiency Is Robust in Adult but Not Neonatal Spfash MiceMolecular Therapy, 2009
- A complex rearrangement in GBE1 causes both perinatal hypoglycemic collapse and late-juvenile-onset neuromuscular degeneration in glycogen storage disease type IV of Norwegian forest catsMolecular Genetics and Metabolism, 2007
- Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?Journal of Hepatology, 2007
- Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8Molecular Therapy, 2006